贵州信邦制药股份有限公司 2025年第一次临时股东大会决议的公告

Meeting Overview - The first extraordinary general meeting of shareholders for 2025 was held on September 17, 2025, at the company's meeting room in Guiyang, Guizhou [5][8] - The meeting was convened by the company's ninth board of directors and was conducted in accordance with relevant laws and regulations [5][39] Attendance - A total of 308 shareholders and authorized representatives attended the meeting, representing 497,817,792 voting shares, which is 26.2506% of the total voting shares [6] - Of these, 10 shareholders attended in person, representing 479,522,871 shares (25.2859% of total voting shares), while 298 participated via online voting, representing 18,294,921 shares (0.9647% of total voting shares) [6][7] Proposals and Voting Results - The proposal for the 2025 semi-annual profit distribution plan received 99.6876% approval from attending shareholders [12] - The proposal to cancel the supervisory board and amend the company’s articles of association was approved with 99.5855% [14] - Various governance system amendments were proposed, with the majority receiving over 97% approval, although some faced significant opposition from minority shareholders [17][19][21][23][25][28][30][32][34][37] Legal Compliance - The meeting was witnessed by legal representatives from Guohao Law Firm, confirming that the meeting's procedures complied with legal and regulatory requirements [39] New Board Member Election - On September 17, 2025, the company elected Ms. Lü Xiangqian as a representative director of the ninth board, with her term starting immediately [42] - Ms. Lü meets all qualifications as per the Company Law and the company’s articles of association [42][45]